High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland.
Nov 24, 2014
not rated yet | 0
New research has shown a protein that controls the growth of new blood vessels could potentially reduce the effects of cardiovascular disease in patients' legs, including risks of leg ulcers, gangrene, and ...
Nov 03, 2014
not rated yet | 1